Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Salbutamol Sulphate,Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PT027 (Albuterol Sulfate) is a potential first-in-class inhaled, fixed-dose combination of albuterol, a short-acting beta2-agonist (SABA), and budesonide, an inhaled corticosteroid (ICS), in the US, being developed by Avillion and AstraZeneca under an ag...
Product Name : PT027
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2022
Lead Product(s) : Salbutamol Sulphate,Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sonelokimab is a novel tri-specific Nanobody® targeting IL 17A and IL-17F that also has an extended half-life and enhanced biodistribution through engineered binding affinity to albumin.
Product Name : M1095
Product Type : Antibody
Upfront Cash : Inapplicable
April 23, 2021
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sonelokinab is a novel investigational IL-17 A/F Nanobody® that neutralizes both IL-17A and IL-17F. The trial met its primary endpoint based on Investigator's Global Assessment at week 12 with clinically meaningful and statistically significant results ...
Product Name : M1095
Product Type : Antibody
Upfront Cash : Inapplicable
October 29, 2020
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable